Swiss Cell & Gene Summit
Join the inaugural Swiss Cell & Gene Summit, an exclusive new forum designed to connect CGT developers, clinical innovators, investors, and manufacturing experts around the most relevant strategic topics shaping the future of cell and gene therapy.
The summit provides a platform for thought leadership, knowledge exchange, and the development of new collaborations across the global CGT community.
**********************************************************
-AGENDA-
09:00 – 09:15 Dr. Martin Kessler, CEO Siegfried DINAMIQS Welcome and opening remarks
09:15 – 09:45 Keynote: Luk H. Vandenberghe, PhD Serial Entrepreneur, Associate Professor Harvard Medical School, Director Grousbeck Gene Therapy Center, Co-Founder and Board Member Lyora Therapeutics, Scientific Founder and Board Member Affinia Therapeutics
"Adapting gene therapy to a new era: innovative technology, shorter clinical derisking, and durable value"
09:45 – 10:15 Anne Marie de Jonge–Schuermans, PhD. Board Member Swiss Biotech Association
"Switzerland`s unique ecosystem driving innovation in cell and gene therapy"
10:15 – 10:45 Shirley Zhu, Founder & CEO of HyQure
“CGT market and strategy in China”
10:45 – 11:00 Coffee break
11:00 – 11:30 Dr. Wei Wang, Co-Founder & CBO Waker Biosciences, Dr. Martin Kessler, CEO Siegfried DINAMIQS
“Connecting Swiss Innovation and Chinese Excellence: New collaboration models for IIT access and clinical execution”
11:30 – 12:15 Panel discussion:
“How Swiss – Chinese collaboration can create the biggest value for the CGT community”
Panelists from VC, BioPharma/ Biotech, Regulatory and China Moderator: Dr. Eduard Ayuso, CTO Siegfried DINAMIQS
12:15– 13:15 Networking lunch and closing discussion
**********************************************************
Switzerland’s position as the world’s leading innovation hub, combined with China’s growing momentum in shaping the global life sciences industry, creates a powerful foundation for advancing cell and gene therapies. In particular, China’s growing experience with investigator initiated trials (IITs) offers a new path to generate early human proof-of-concept data enabling more targeted development and investment decisions.
Together, these strengths bring the scientific excellence, clinical ambition, manufacturing know how, and market dynamic needed to accelerate the development of more effective therapies and improve outcomes for patients.
This event will look into how developers and investors can benefit from the best of both worlds.
Why attend? Gain a practical view of how Swiss and Chinese partners may support CGT development, understand the perspectives of key stakeholders, and identify partnership routes to move from opportunity to execution.